Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Related articles:
Related suggestion:
Beyond Meat urges investors to look past bumpy Q1, says new US burger could reignite salesTrump hush money trial: Defense attorneys attacks Stormy Daniels' credibilityBank of England expected to wait for more evidence that inflation is under control before rate cutNorth West joins starry concert event of 'The Lion King' at Hollywood BowlWhy as a slim woman, I always have to tread on eggshells around my overweight friendsRussia: Victory Day celebration is a key pillar of Putin’s ruleContreras' injury highlights the danger of big league catchers moving closer to home plateKevin McCloud builds his very OWN Grand Designs: TV star, 64, transforms 400Connecticut lawmakers adjourn session, fail to pass AI regulations but pass absentee ballot reformsMateo's go
3.2513s , 6606.265625 kb
Copyright © 2024 Powered by Chinese inhibitor drug candidate becomes first to enter phase ,Worldly Window news portal